Merck Animal Health’s Bravecto Quantum approved by FDA

Merck’s (MRK) Animal Health division announced the FDA approved an expanded label for Bravecto Quantum in dogs. The updated indication adds treatment and control of Asian longhorned tick and Gulf Coast tick for 12 months, when administered as a single, veterinarian-delivered injection. Bravecto Quantum was approved in the U.S. on July 10, 2025, and continues to be indicated to kill adult fleas, for the treatment and prevention of flea infestations, and for the treatment and control of Ixodes scapularis, Dermacentor variabilis, and Rhipicephalus sanguineus infestations for 12 months and A. americanum infestations for 8 months in dogs and puppies 6 months of age and older. Bravecto Quantum remains available exclusively through licensed veterinarians.